Elanco
Elanco is a global leader in animal health, dedicated to transforming animal care by providing innovative solutions that improve animal health and wellbeing. With a purpose of making life better for animals, Elanco fosters a culture of integrity, respect, and excellence, and is committed to sustainability and societal impact. The company has a rich history of over 70 years of innovation, operates multiple manufacturing sites worldwide, and invests in research, development, and strategic partnerships to bring high-impact innovations to market. Elanco is a purpose-driven company with a strong focus on innovation, sustainability, and improving outcomes for animals, customers, and society.
Industries
Nr. of Employees
Very Large (1000+)
Products
Multi-species animal vaccines
Vaccines formulated and manufactured for multiple animal species to prevent infectious diseases at commercial scale.
Therapeutic biologics for animal health
Biologic therapies produced for clinical use in animals, including monoclonal antibody-based treatments.
Companion animal wellness and preventive products
Preventive care and wellness products for companion animals intended for use by pet owners and veterinarians.
Multi-species animal vaccines
Vaccines formulated and manufactured for multiple animal species to prevent infectious diseases at commercial scale.
Therapeutic biologics for animal health
Biologic therapies produced for clinical use in animals, including monoclonal antibody-based treatments.
Companion animal wellness and preventive products
Preventive care and wellness products for companion animals intended for use by pet owners and veterinarians.
Services
Partnerships to advance external research, platforms or molecules through R&D toward commercialization, with mechanisms for proposal submission and collaborative engagements.
Coordination with external manufacturing partners to expand global production capacity for commercial supply.
Regulatory strategy, submission support and development planning spanning preclinical research through licensure for animal health products.
Onsite pilot manufacturing and process development services to translate lab-scale processes to manufacturing-ready workflows.
Laboratory testing, quality control data generation and batch release assistance to support product commercialization and regulatory compliance.
Digital measurement and reporting services for farm-level environmental footprint metrics and integration with verification or carbon insetting marketplaces.
Partnerships to advance external research, platforms or molecules through R&D toward commercialization, with mechanisms for proposal submission and collaborative engagements.
Coordination with external manufacturing partners to expand global production capacity for commercial supply.
Regulatory strategy, submission support and development planning spanning preclinical research through licensure for animal health products.
Onsite pilot manufacturing and process development services to translate lab-scale processes to manufacturing-ready workflows.
Laboratory testing, quality control data generation and batch release assistance to support product commercialization and regulatory compliance.
Digital measurement and reporting services for farm-level environmental footprint metrics and integration with verification or carbon insetting marketplaces.
Expertise Areas
- Biologics manufacturing
- Vaccine development and manufacturing (multi-species)
- Pilot-scale process development and scale-up
- Clinical trial design and operations (animal health)
Key Technologies
- Mammalian cell biologics production
- Vaccine production platforms and species-specific formulation
- Pilot plant process scale-up
- Automated process control systems
News & Updates
Elanco announced it received a positive opinion on Zenrelia (ilunocitinib) from the European Union’s Committee for Veterinary Medicinal Products.
Elanco received USDA approval for Trucan™ Ultra CIV (Canine Influenza Vaccine), providing a high standard of respiratory protection.
Elanco announced milestones in expanding access to CPMA for veterinarians and shelters.
Elanco focuses on delivering high-impact innovation through a collaborative R&D and manufacturing process, with a global network of 17 manufacturing sites and 11,000 SKUs.
Elanco's purpose-driven approach aims to improve outcomes for animals, customers, and society through innovative solutions and sustainable practices.
Elanco implements fierce brand protection measures to combat illicit trade, counterfeit products, and protect consumer trust.
Elanco announced it received a positive opinion on Zenrelia (ilunocitinib) from the European Union’s Committee for Veterinary Medicinal Products.
Elanco received USDA approval for Trucan™ Ultra CIV (Canine Influenza Vaccine), providing a high standard of respiratory protection.
Elanco announced milestones in expanding access to CPMA for veterinarians and shelters.
Elanco focuses on delivering high-impact innovation through a collaborative R&D and manufacturing process, with a global network of 17 manufacturing sites and 11,000 SKUs.
Elanco's purpose-driven approach aims to improve outcomes for animals, customers, and society through innovative solutions and sustainable practices.
Elanco implements fierce brand protection measures to combat illicit trade, counterfeit products, and protect consumer trust.